CliffBio
small molecule

XELJANZ XR

TOFACITINIB CITRATE

Loss of exclusivitySeptember 2034latest FDA-listed patent expiry
CompanyPfizer →View the full company profile on CliffBio

Drug detail

Brand nameXELJANZ XR
Active ingredientTOFACITINIB CITRATE
StrengthEQ 11MG BASE
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2016
Marketing statusRX

Listed patents

PatentExpiresType
9937181*PEDSeptember 2034—
11253523*PEDSeptember 2034—
11253523March 2034use U-3329
9937181March 2034product
RE41783*PEDJune 2026—
RE41783December 2025substance

More from Pfizer

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

XELJANZ XR patent cliff — loss of exclusivity September 2034 | CliffBio